June 17, 2021

To provide an update on Phase 2b/3 clinical trial for CureVac’s first-generation COVID-19 vaccine candidate, CVnCoV, CureVac N.V. (Nasdaq: CVAC) hosted a webcast and conference call on Thursday, June 17, 2021, at 2:00 p.m. CEST / 8:00 a.m. EST.

The corresponding press release, presentation slides and transcript can be found under “Downloads”. An archived webcast can be found under "Links".